Skip to content

OptimizeRx OPRX Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

Veeva Systems logo
Veeva SystemsVEEV
-$262.53M-1,388%
Spectral AI, Inc. logo
Spectral AI, Inc.MDAI
-$1K-100%
Claritev Corporation logo
Claritev CorporationCTEV
$98.93M+35.2%

Other financials

Income statement

See full
Revenue$19.8M-9.5%
Gross profit$14.9M+11.9%
Operating income$396.0K+119%
Net income-$495.0K+77.5%
EPS (diluted)-$0.03+75.0%

Balance sheet

See full
Cash & equivalents$20.2M+21.7%
Total debt$23.7M-27.7%
Total equity$129.6M+11.5%
Total assets$167.3M-0.3%

Cash flow

See full
Operating cash flow-$467.0K-112%
CapEx$21.0K-22.2%
Free cash flow-$488.0K-113%

Valuation

See full
Market cap$107.34M-54.1%
Enterprise value$110.88M-55.0%
P/E15.7×
P/S-1.2×

Profitability

See full
Gross margin70%+14.1pp
Operating margin13.2%
Net margin6.4%+3.6pp
FCF margin13.4%+4.8pp

Returns & leverage

See full
Return on equity5.6%+3.3pp
Debt / equity0.2×-0.1×
Current ratio5.4×+2.6×

Where this comes from

Reported directly by OptimizeRx in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: OptimizeRx’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about OptimizeRx's cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OptimizeRx's cash provided by (used in) financing activity, including discontinued operation?
OptimizeRx (OPRX) reported cash provided by (used in) financing activity, including discontinued operation of -$2.71M in Q1 2026.
How has OptimizeRx's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
OptimizeRx's cash provided by (used in) financing activity, including discontinued operation decreased by 361.3% year-over-year, from -$587K to -$2.71M.
What is the long-term trend for OptimizeRx's cash provided by (used in) financing activity, including discontinued operation?
Over 4 years (2021 to 2025), OptimizeRx's cash provided by (used in) financing activity, including discontinued operation has grown at a -41.3% compound annual growth rate (CAGR), from $73.92M to -$8.8M.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.